Pfizer Inc. (NYSE:PFE) Holdings Lowered by Obermeyer Wood Investment Counsel Lllp

Obermeyer Wood Investment Counsel Lllp reduced its holdings in Pfizer Inc. (NYSE:PFE) by 10.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,748 shares of the biopharmaceutical company’s stock after selling 3,984 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Pfizer were worth $1,029,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Moneta Group Investment Advisors LLC raised its stake in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after purchasing an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley grew its holdings in Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after buying an additional 348,628 shares during the last quarter. Norges Bank acquired a new stake in Pfizer in the 4th quarter valued at approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA grew its holdings in Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after buying an additional 5,185,453 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PFE. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Price Performance

PFE traded up $0.16 during trading on Friday, hitting $25.55. The company’s stock had a trading volume of 7,637,767 shares, compared to its average volume of 41,995,176. The firm’s 50 day moving average price is $27.14 and its two-hundred day moving average price is $28.74. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The stock has a market capitalization of $144.68 billion, a price-to-earnings ratio of 70.51, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.14 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.